Physician profile
Todd Kerwin
NPI 1457347999
$4,409.54
in general payments reported to CMS, 2019-2025
23 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $67.29 · 2021: $252 · 2022: $697 · 2023: $2,636 · 2024: $269 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541 · Travel and Lodging: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.75 |
| Travel and Lodging | $1,516.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,005.30 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $322.41 | 2023 | Assure Wcd |
| Abbott Laboratories | $303.13 | 2022-2024 | Cardiomems, Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $287.80 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.20 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $150.62 | 2022-2024 | |
| Pfizer INC. | $142.82 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $133.17 | 2020-2024 | Eliquis, Camzyos |
| Biotronik INC. | $131.01 | 2019-2023 | Selectra |
| Vivaquant INC, Dba Rhythm Express | $129.84 | 2025 | Rhythm Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.78 | 2022 | |
| Merck Sharp & Dohme LLC | $100.21 | 2021-2022 | |
| Amgen INC. | $94.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.97 | 2019 | |
| Genzyme Corporation | $44.77 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.96 | 2022 | |
| Impulse Dynamics (USA) INC. | $36.17 | 2024 | Optimizer |
| Siemens Medical Solutions USA, INC. | $31.43 | 2020-2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Actelion Pharmaceuticals US, INC. | $29.16 | 2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $18.04 | 2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2023 | |
| Chiesi USA, INC. | $14.53 | 2020 | |
| Boston Scientific Corporation | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kerwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.